%0 Journal Article %A Shih-Wei Lo %A Ming-Hsin Li %A Shih-Min Wang %A Ming-Wei Chen %A wei-lin lo %T Evaluation of MH-PC-AB-53 peptideas a carcinoma therapeutic agent %D 2020 %J Journal of Nuclear Medicine %P 3114-3114 %V 61 %N supplement 1 %X 3114Objectives: MH-PC-AB-53 showed high binding affinity for prostate-specific membrane antigen. Radiolabeled PSMA peptides that are prostate specific can be used for prostate -targeted radiotheragnostic application. The MH-PC-AB-53 (15-30μg) was labeled with ~3 or ~6mCi InCl3 (from INER) in sodium acetate (NaOAc) with different pH values (4.0-6.0) at 95℃ within 15mins. After labeling with In-111, quality control was performed by RP-HPLC and radio thin layer chromatography. Radiochemical purity was analyzed in the radio-TLC scanner with a 0.1M citric acid solution as the mobile phase. The Rf of free In-111 was approximately 0.95, and the Rf of 111In -MH-PC-AB-53 was approximately 0.05. The Radiochemical purity of the 111In-MH-PC-AB-53 was assayed by TLC(96.8%) and HPLC (96%). LNCaP tumor bearing mice were intravenously injected with 111In -MH-PC-AB-53. Scans were performed 1, 4, and 24 h after the administration. 111In-MH-PC-AB-53 showed high tumor uptake at all time points. %U